AI illustration · not actual product photoDetails from the source.
This catalogue entry records LL-37, 5 mg × 10 vials (SKU 375), using the supplied source listing. The cited dossier describes: Research has focused on innate host defense, antimicrobial and immunomodulatory activity, and wound biology. Human investigations have tested specific topical LL-37 preparations for venous leg ulcers and diabetic foot ulcers. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- 375
- Source specification
- 5mg*10vials
- Source document
- PriceList(1).pdf, page 3
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
LL37 is commonly the name for the 37-amino-acid human cathelicidin host-defense peptide, a peptide. The supplied catalogue lists SKU 375, specification *10vials, price 86 per 10 vials (currency not stated). That label does not verify the composition or exact identity of the supplier vial.
Biological mechanism
Endogenous LL-37 is released when the hCAP18 precursor is cleaved extracellularly. Laboratory research describes antimicrobial membrane effects and binding of bacterial endotoxins. LL-37 also affects immune-cell recruitment, inflammation, endothelial and wound-cell behavior. Effects are context-dependent and can be pro- or anti-inflammatory; laboratory work also reports cytotoxicity to human cells at some concentrations.
Research focus
Research has focused on innate host defense, antimicrobial and immunomodulatory activity, and wound biology. Human investigations have tested specific topical LL-37 preparations for venous leg ulcers and diabetic foot ulcers. In-vitro and animal findings, including antimicrobial activity and wound vascularization, are preclinical and not proof of human therapeutic benefit.
Potential applications in the evidence
Topical wound healing in chronic venous leg ulcers and diabetic foot ulcers has been investigated, alongside laboratory research into antimicrobial and host-defense activity. These are research areas only; evidence does not establish a clinical application for the listed vial or other routes or uses.
Human evidence
Human evidence is limited to studies of specific topical preparations. A small randomized study in 34 people with venous leg ulcers reported healing signals, but a later phase IIb randomized placebo-controlled study in 148 people found no significant overall improvement; favorable results in a larger-ulcer subgroup were post hoc and need confirmation. A separate diabetic-foot-ulcer randomized study enrolled 25 participants and reported a difference in granulation index, but not significant between-group differences in wound-area reduction, inflammatory markers, or bacterial colonization. These studies do not establish efficacy or safety for the exact catalogue vial.
Known and potential effects
Limited topical wound studies reported no notable systemic safety signal; one participant in the 25-person diabetic-foot-ulcer study had mild irritant contact dermatitis, which investigators did not attribute directly to LL-37. Laboratory research reports cell cytotoxicity and context-dependent immune/inflammatory effects. Small topical studies cannot establish safety for other preparations or routes.
Safety and contraindications
FDA reports potential immunogenicity and peptide-impurity/API-characterization concerns for compounded LL-37 and says it lacks sufficient safety-related information to know whether it could cause harm in humans. FDA also cites nonclinical findings suggesting detrimental effects on male reproduction and protumorigenic effects in some tissues; these are potential signals, not proof of effects from this vial. The catalogue and reviewed sources do not establish product-specific contraindications. Exact vial identity and quality are unknown.
U.S. FDA / regulatory status
No FDA-approved LL-37 drug product was identified in the official FDA material reviewed. FDA's compounding-safety page lists cathelicidin LL-37 among bulk-substance nominations that were withdrawn and describes unresolved safety concerns. A compounding nomination or withdrawal is not marketing approval. The catalogue gives no manufacturer, lot, formulation, source, jurisdiction, or approval documentation, so the precise regulatory status of this vial cannot be verified and must not be inferred from any separately studied formulation.
Evidence limitations
Mechanistic evidence is largely in vitro or animal-based. Human evidence is limited to a few route- and formulation-specific wound studies with mixed efficacy findings and limited generalizability. The phase IIb trial's favorable larger-wound subgroup result was post hoc and its publication disclosed company funding and employee conflicts. The exact listed vial's composition, quality, manufacturer, regulatory status, and clinical evidence are unverified. No evidence reviewed establishes benefits or risks for a combination product.
Supporting sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration · Official regulator safety and compounding information. Supports: FDA's compounding-related safety concerns, limited safety information, potential immunogenicity and characterization issues, nonclinical reproductive and tumorigenicity signals, and distinction from drug-product approval.
- Human antimicrobial host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update Inflammation Research, via PubMed Central · Peer-reviewed review. Supports: Peptide identity and precursor processing, antimicrobial and immune mechanisms, context-dependent inflammation, and laboratory-reported cytotoxicity.
- Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial Wound Repair and Regeneration, indexed by PubMed · Primary human randomized controlled trial. Supports: Small human topical study design, reported healing signals, and reported safety observations.
- Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial Wound Repair and Regeneration, via PubMed Central · Primary human phase IIb randomized controlled trial. Supports: Larger human trial's lack of significant overall efficacy, exploratory subgroup finding, topical context, and disclosed funding/conflicts.
- Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial Archives of Dermatological Research, via PubMed Central · Primary human randomized controlled trial. Supports: 25-person diabetic-foot-ulcer study outcomes, limited efficacy findings, mild irritant dermatitis observation, and study limitations.